Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3

Citius Pharmaceuticals, Inc.

One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.
Board amended bylaws reducing stockholder meeting quorum from majority to one-third to avoid adjournment risk.
Series A has no conversion, dividend, or liquidation rights; redeemed for $100 automatically after vote results announced.
Special meeting called; preliminary proxy filed for shareholder vote on the authorized share increase.

item 1.01 item 5.03 item 3.02 item 3.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.